| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Immunic Inc. | IMU-838 | Crohn’s disease | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Immunic Inc. | Vidofludimus calcium (IMU-838) - (RAPID_REVIVE) | Post COVID Syndrome | Phase 2 | Enrollment Initiation | Oral | N/A |
| Immunic Inc. | Vidofludimus Calcium - (ENSURE) | Progressive Multiple Sclerosis | Phase 3 | Ongoing | Oral | Neurology |
| Immunic Inc. | Vidofludimus Calcium (IMU-838) - (CALLIPER) | Progressive Multiple Sclerosis | Phase 2 | Data Released | Oral | Neurology |
| Immunic Inc. | IMU-838 - (CALVID-1) | COVID-19 | Phase 2 | Data Released | oral | COVID-19 |
| Immunic Inc. | IMU-838 - (CALDOSE-1) | Ulcerative colitis | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Immunic Inc. | IMU-838 | Primary Sclerosing Cholangitis | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Immunic Inc. | IMU-838 and Oseltamivir (Tamiflu) - (IONIC) | COVID-19 | Phase 2b | Trial Completed | Oral | COVID-19 |